Search - tctmd.com

Displaying 401 - 420 of 477

Sort: Relevancy | Date

Ecarin Clotting Time (ECT) more accurately reflects bivalirudin concentration than Activated Clotting Time (ACT) in patients undergoing Percutaneous Coronary Intervention using...

Presentation TCT 2013

Ecarin Clotting Time (ECT) more accurately reflects bivalirudin concentration than Activated Clotting Time (ACT) in patients undergoing Percutaneous Coronary Intervention using...

Presenter: Ronan Margey, Helen Ridgway, Richard Rullman, Jeff Spencer, Ronan Margey, Iris McNulty, Aditya Mangla, Sotir Polena, Daniel Soffer, Ik-Kyung Jang

January 31, 2013

Double (360mg) Loading Dose Of Ticagrelor In Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Presentation TCT 2013

Double (360mg) Loading Dose Of Ticagrelor In Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Presenter: Dimitrios Alexopoulos, Ioanna Xanthopoulou, Vassilios Gkizas, George Kassimis, Konstantinos Theodoropoulos, Tsigkas Grigorios, Ioannis Chiladakis, Anastasia Damelou, George Hahalis, Periklis Davlouros

January 31, 2013

Discontinuation of Long-Term Clopidogrel Therapy is Associated with Death and Myocardial Infarction after Saphenous Vein Graft Percutaneous Coronary Intervention

Presentation TCT 2013

Discontinuation of Long-Term Clopidogrel Therapy is Associated with Death and Myocardial Infarction after Saphenous Vein Graft Percutaneous Coronary Intervention

Presenter: Amit Sachdeva, Sumati Bavisetty, Gerald Beckham, Albert Shen, Vicken Aharonian, Prakash Mansukhani, Gregg Stone, Martin Leon, Jeffrey Moses, Naing Moore, Ric Hyett, Richard Contreras, Somjot Brar

January 31, 2013

Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-Eluting Stents: Insight From the Florence Left Main-PCI Registry

Presentation TCT 2013

Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-Eluting Stents: Insight From the Florence Left Main-PCI Registry

Presenter: Renato Valenti, Angela Migliorini, Guido Parodi, Ruben Vergara, Nazario Carrabba, Emilio Vincenzo Dovellini, David Antoniucci

January 31, 2013

Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

Presentation TCT 2013

Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

Presenter: Andreas Baumbach, Harold Dauerman, Bernardo Cortese, Martial Hamon, Jayne Prats, Efthymios Deliargyris, Roxana Mehran, Gregg Stone

January 31, 2013

Can Amelioration of HDL-C Level by Pitavastatin Improve Clinical Outcomes in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention?

Presentation TCT 2013

Can Amelioration of HDL-C Level by Pitavastatin Improve Clinical Outcomes in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention?

Presenter: Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Amro Elnagar, Sung Il Im, Sun Won Kim, Jin Oh Na, Seong Woo Han, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh, Myung Ho Jeong

January 31, 2013

News Conference News TCT 2012

Aspirin, Cilostazol Combination Best After Angioplasty for Critical Limb Ischemia

November 01, 2012

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Presentation TCT 2012

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Presenter: Rajesh Dave

October 25, 2012

$Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!$

Presentation TCT 2012

Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!

Presenter: Gilles Montalescot

October 25, 2012

Debate: Bivalirudin Is the Preferred Anticoagulant Strategy During STEMI!

Presentation TCT 2012

Debate: Bivalirudin Is the Preferred Anticoagulant Strategy During STEMI!

Presenter: Roxana Mehran

October 25, 2012

Part 2: Antiplatelet Agents

Presentation TCT 2012

Part 2: Antiplatelet Agents

Presenter: Robert Harrington

October 25, 2012

Part 1: Oral Anticoagulants

Presentation TCT 2012

Part 1: Oral Anticoagulants

Presenter: Christopher Granger

October 25, 2012

Debate: Clopidogrel is Enough and Still Plays a Role for Most!

Presentation TCT 2012

Debate: Clopidogrel is Enough and Still Plays a Role for Most!

Presenter: Michael Love

October 25, 2012

ADAPT-DES One Year: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Presentation TCT 2012

ADAPT-DES One Year: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Presenter: Gregg Stone

October 25, 2012

Ticagrelor Update: PLATO: Recent Analyses

Presentation TCT 2012

Ticagrelor Update: PLATO: Recent Analyses

Presenter: Robert Harrington

October 24, 2012

Rivaroxaban Update: ATLAS-ACS-2 TIMI-51: Recent Analyses and FDA Redux

Presentation TCT 2012

Rivaroxaban Update: ATLAS-ACS-2 TIMI-51: Recent Analyses and FDA Redux

Presenter: C. Michael Gibson

October 24, 2012

Prasugrel Update: TRILOGY

Presentation TCT 2012

Prasugrel Update: TRILOGY

Presenter: E. Magnus Ohman

October 24, 2012

Prasugrel Is the Gold Standard!

Presentation TCT 2012

Prasugrel Is the Gold Standard!

Presenter: Matthew Price

October 24, 2012

GP IIb/IIIa Inhibition: New Studies, New Insights

Presentation TCT 2012

GP IIb/IIIa Inhibition: New Studies, New Insights

Presenter: David Moliterno

October 24, 2012

Factor IXa Inhibition (Aptamer) Update

Presentation TCT 2012

Factor IXa Inhibition (Aptamer) Update

Presenter: Roxana Mehran

October 24, 2012

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.